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Summary
Childhood obesity results in premature atherosclerosis and requires early interven-
tion. Compare the effectiveness of 6-month lifestyle interventions (with choice of
either individual or group therapy) with standard care on body mass index (BMI) z-
score and cardiovascular disease (CVD) risks factors in children with obesity.
This 6-month randomized controlled trial with a 6-month follow-up included 74 pre-
pubertal children with obesity (7.5-11.9 years) assigned randomly (2:1) to interven-
tion or control. Families in the intervention arm choose between an individually deliv-
ered treatment (3 hours paediatrician + 4 hours dietician) or group treatment
(35 hours with a multidisciplinary team). Children participated also to a weekly physi-
cal activity programme. We measured BMI, BMI z-score; waist circumference (WC);
total and abdominal fat; blood pressure; common carotid artery intima-media thick-
ness and incremental elastic modulus (Einc); endothelium-dependent and indepen-
dent dilation (nitroglycerin-mediated dilation [NTGMD]) of the brachial artery; fasting
plasma glucose, insulin, lipids; and high-sensitivity C-reactive protein (hs-CRP). Com-
pared to controls, at 6 months, abdominal fat and hs-CRP were reduced in both inter-
ventions. The group intervention was also effective in reducing BMI (−0.55 kg/m2;
95% confidence interval −1.16 to 0.06) and BMI z-score (−0.08; −0.15 to 0.00) at
6 months and BMI, BMI z-score, WC, NTGMD, total and abdominal fat at 12 months.
Abdominal fat and low-grade inflammation were significantly decreased in both
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interventions. High-intensity group treatment improved early signs of atherosclerosis
in children with obesity. These findings are important for the promotion of car-
diometabolic health in this population.
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1 | INTRODUCTION
Non-communicable diseases (NCDs) have overtaken infectious dis-
eases as the world's major global disease burden. Among NCDs, car-
diovascular diseases (CVDs) account for nearly half the total burden
and are the leading cause of death globally.1 Childhood obesity lays
the foundation for CVDs and has a strong tendency to track into
adulthood if left untreated.2 Childhood therefore presents a unique
opportunity for intervention to prevent lifelong exposure and prema-
ture morbidity, and control associated health costs.
Multidisciplinary programmes are considered the gold standard
treatment for children with obesity.3 Family-based behavioural inter-
ventions were initially developed to modify the shared family environ-
ment, provide role models and support child behaviour changes.4
Treatment in groups without individual attention has been shown to
be both effective and cost-effective.5 Medium (26-75 hours contact
time) to high-intensity (>75 hours contact time) interventions are
more effective than lower ones (<25 hours) with a small to moderate
improvement in weight status.6
In 2007 we developed, in cooperation with the Swiss Federal
Office of Public Health, a large-scale national programme for the man-
agement of childhood obesity using a standardized intensive group
treatment covered by health insurances. However, the national evalu-
ation study showed that only 0.8% of patients could be included in a
group programme due to travelling time, parents “work and intensity
of intervention.”7 This type of treatment is also quite resource inten-
sive, with multiple healthcare workers required to meet different age
groups of children and their parents. A recent Cochrane review of life-
style interventions for the treatment of obesity in children aged 6 to
11 years concluded that there is insufficient evidence to determine
the most effective and sustainable type or setting of intervention.8
The aim of this study was to compare the effectiveness of
6-month lifestyle interventions (with choice of either individual or
group therapy) with standard care on body mass index (BMI) z-score
and CVD risk factors.
2 | MATERIALS AND METHODS
2.1 | Study design, setting and participants
This randomized controlled trial (RCT) included 74 pre-pubertal new
patients with obesity aged 7.5 to 11.9 years who were recruited over
a 4-year period at the Obesity Clinic of the Children's Hospital of
Geneva (tertiary centre), if their BMI was >97th age- and gender-
specific percentile according to the World Health Organization
(WHO) references.9 The report of this trial conforms to CONSORT
2010 guidelines and the Template for intervention description and
replication checklist.
Subjects were excluded from the study if they: (a) had a Tanner stage
assessed by clinical examination (size of the breasts or testicular volume,
and development of pubic hair) >1; (b) were involved in any weight con-
trol, physical activity, behavioural intervention or bariatric surgery; (c) had
a family history of dyslipidaemia or essential hypertension; (d) took any
medications or hormones that could affect cardiovascular function, body
composition, lipid or glucose metabolism; (e) had an orthopaedic condition
that limited physical activity; (f) had a genetic disorder or another chronic
disease; and (g) received therapy for psychiatric problems.
The Ethics Committee of the University Hospitals of Geneva
approved this study and informed written consent was obtained from
all participating parents and children.
WHAT IS ALREADY KNOWN ABOUT THIS
SUBJECT
• Multi-component programmes are considered the gold
standard treatment for children with obesity.
• There is insufficient evidence to determine the most effec-
tive and sustainable type or setting of lifestyle intervention.
WHAT THIS STUDY ADDS
• Individually delivered or group lifestyle interventions dur-
ing 6 months resulted in significant reductions in abdomi-
nal fat and low-grade inflammation in pre-pubertal
children with obesity, compared to standard care.
• To our knowledge, this is the first study showing such
changes after an individually delivered intervention in this
population.
• High-intensity group intervention was also effective in
reducing body mass index (BMI) and BMI z-score, com-
pared to standard care, as well as vascular reactivity medi-
ated by smooth muscle cells and carotid arterial stiffness.
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2.2 | Randomization and concealment
Enrolment, randomization, interventions and follow-up of study par-
ticipants are summarized in Figure 1; 74 subjects were randomly
assigned (2:1) to a 6-month lifestyle intervention (n = 52) or a control
group (C, n = 22, standard care) arm. Sealed opaque envelopes con-
taining two-thirds of intervention and one-third of control were used.
In order to facilitate the implementation of this research into clinical
practice, children and parents who were selected in the intervention arm
could choose to participate in a moderate-intensity individually delivered
intervention (treatment A, n = 21) or a high-intensity group delivered
intervention (treatment B, n = 31), according to their will and availability.
During the 6-month follow-up period, groups A and B were invited to
attend two paediatric consultations (45 minutes.) at 9 and 12 months.
2.3 | Interventions
During the pilot phase of the study, an adapted mastery approach
“Contrepoids” was developed and evaluated with 10 volunteer fami-
lies. The manual contained modules on healthy nutrition, physical
activity, family habits, parenting and coping with psychosocial prob-
lems commonly experienced by children with obesity, such as teasing
and body image concerns. The nutrition education component used a
healthy eating approach encouraging low saturated fat and nutrient-
dense food (vegetables, fruits and whole grain foods) and portion size
moderation. Modules included food choices, balanced meals, carbon-
ated and non-carbonated sugar-sweetened beverages, food promo-
tion and labelling, healthy cooking recipes, recognition of hunger and
satiety, eating disorders, management of high-risk situations and
F IGURE 1 Flowchart for enrolment,
randomization, intervention and follow-
up of study participants
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prevention of relapses. The physical activity component focused on
encouraging active transport (walking, biking), use of stairs, leisure-
time activities and sport and reduction of sedentary behaviours
(television, computer and electronic games). Self-awareness, problem-
solving, goal setting, stimulus control, coping skills training, empower-
ment, parental guidance and relapse prevention behaviour change
techniques were used. At the end of each session, individual goals
were set and participants received homework to complete before the
next one. Therapists communicated at least weekly with the physical
education teachers to reinforce behavioural changes. The moderate-
intensity individually delivered intervention (treatment A) comprised
7 monthly 60-minute sessions with the child and his/her parent/s
(at least the mother), which were conducted by a trained paediatrician
(at 0, 3 and 6 months) and a dietician (at 1, 2, 4 and 5 months). Parents
could choose a convenient appointment time which could be changed
if unexpected events arose. Similar mastery approach and education
manuals “Contrepoids” were used in both treatment arms, but topics
were chosen according to family needs in individual care.
The high-intensity group delivered intervention (treatment B)
comprised 14 sessions (11 weekly then 3 monthly meetings, total
35 hours) over a 6-month period. Ideally both parents, but at least the
mother, were asked to participate. Parental and child sessions were
held separately. The parental group sessions consisted of 90 minutes
with a dietician (at all sessions), a psychologist trained in cognitive
behavioural therapy (at least four sessions) or a paediatrician experi-
enced in therapeutic patient education. The child sessions consisted
of 60 minutesutes with the same therapists. Each group included
10 to 12 children and their parents.
Controls (group C) received standard care for 12 months, which
included four 45-minute paediatric consultations (every 3 months)
and instruction to maintain their current level of physical activity.
Treatment groups A and B could participate in a 6-month after
school moderate-to-vigorous physical activity training programme
including two sessions of 60 minutes per week (total 44 hours between
September-October and March-April), in addition to school physical
education (135 minutes/week). Children who were already enrolled in a
sports club (at least 60 minute/week 6 months/year) attended only one
physical activity session per week at the Children's Hospital.
One session per week was organized at the gym hall and the other
one at the swimming pool, under close supervision of two physical
education teachers. Training sessions included 40 minutes of aerobic
exercise, 10 minutes of resistance training of the legs, arms and trunk
and 10-minute of stretching. The intensity was progressively
increased during the 6-month period, to reach intermittent vigorous
intensities. During each session, physical education teachers discussed
theoretical aspects of exercise such as discomfort, sweating and
fatigue in relation to intensity, progress, self-esteem, benefits on
health and well-being, leisure-time physical activity and active trans-
port. Children and parents received a pedometer to assess and
increase progressively their number of steps per day. The final goal
was to do 10 000 steps per day for adults and 12 000 to 13 000 steps
for children.
2.4 | Adverse events
Adverse events were recorded in both groups during the 6-month
active intervention period.
2.5 | Procedures
All measurement techniques have been described in detail, in our pre-
vious publications.10,11 All subjects underwent an identical testing
protocol starting at 8 AM at the Pediatric Research Platform, and a sec-
ond visit was generally needed due to the long duration of testing
(5 hours). The protocol was repeated at 6 and 12 months. The person-
nel of the Pediatric Research Platform and of the Paediatric Cardiol-
ogy Unit were blind to group allocation, whereas subjects and
intervention delivery staff could not be blinded.
2.6 | Primary outcome measures
Body weight (Seca 701, Germany) and standing height were mea-
sured; BMI (weight/height squared, kg × m−2) and BMI z-score (pri-
mary outcome) were calculated using the United States Centre for
Disease Control (BMICDC),
12 and the WHO (BMIWHO) references.
9
2.7 | Secondary outcome measures
Total body fat, abdominal fat and fat-free mass (FFM [kg]), were
assessed using dual-energy X-ray absorptiometry (GE Lunar Prodigy,
Lunar Corp.). Resting blood pressure (office BP) was measured three
times at a 2-minute interval (Philips SureSigns VS3, Philips Medical Sys-
tem, Andover), the average BP was calculated and hypertension was
defined as BP >95th gender-, age- and height-specific percentiles.13
The 24-hour ambulatory BP was assessed every 30 minutes at the
non-dominant arm (Dyasis Integra II, Physicor S.A., France). The
24-hour mean BP and z-scores were calculated, and hypertension was
defined as 24-hour BP >95th age- and gender-specific percentile.14
The common carotid intima-media thickness (CIMT) was measured
using a real-time B-mode ultrasound imager (Vingmed CFM800C Sys-
tem Ltd, Norway and Iôtec System, Iôdata Processing, France).10
Advanced vascular age was defined as CIMT >25th percentile using
45-years-old references.15
The pulse wave of the radial artery was assessed using an
applanation tonometry probe (SphygmoCor; Atcor Medical Ltd.,
Australia) to estimate central aortic pressure non-invasively and deter-
mine arterial stiffness using the incremental elastic modulus (Einc).
After 30 minutes of rest in a recumbent position, the flow-
mediated dilation (FMD) and nitroglycerin-mediated dilation
(NTGMD) of the brachial artery were measured.
Cardiorespiratory fitness was assessed as the maximal oxygen
consumption (VO2 peak) by direct gas analysis (Vmax Spectra, Vyasis
Healthcare, GE) during a multi-stage treadmill test (Marquette
2000, GE).
Physical activity level was assessed using a uniaxial accelerometer
(Actigraph GMT1, MTI, Florida), worn on the right waist during a
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7-day period (30-second cycle, school week, 24 hours/day), except
during bathing or swimming. Data was expressed as mean activity
counts per minute between 8 AM and 9 PM, if the monitor was worn
during ≥4 days including one week-end day. Zero activity periods of
20 minutes or longer were interpreted as being due to unworn accel-
erometers and were removed from the total count.
Blood samples were collected at 8 AM via venepuncture following
a 10-hour overnight fast. Total cholesterol, high-density lipoprotein
cholesterol, triglycerides (TGs) levels (mmol × L−1) concentrations
were determined by standard automotive techniques. Low-density
lipoprotein cholesterol (LDL-C) was calculated using the Friedewald's
formula. Plasma insulin concentrations were measured by radioimmu-
noassay and insulin resistance was assessed by using the homeostasis
model assessment (HOMA-IR), according to the equation: HOMA-
IR = fasting insulin (μU × mL−1) × fasting glucose (mmol × L−1)/22.5.
High-sensitive C-reactive protein (hs-CRP) level was measured by
nephelometry. Results were considered as abnormal according to the
Integrated Guidelines for Cardiovascular Health and Risk Reduction in
Children and Adolescents of the US National Heart, Lung, and Blood
Institute (2012) and International Diabetes Foundation guidelines.
Serum cardiovascular risk biomarkers (serum level of cytokine [CCL2],
adiponectin and neutrophil product [MMP-8]) were also measured in
a sub-sample of 48 children and results are published elsewhere.16
2.8 | Sample size and statistical analysis
The sample size calculation was based on our previous RCT in the
same age group.11 For an anticipated effect size of 0.1 for BMI z-score
(SD 0.1), a sample size of 16 subjects in each group was required to
detect a statistically significant differences at P < .05 with a statistical
power of 80% (β = 0.80).
An intention-to-treat analysis (ITT, n = 74) was performed. Data
were screened for normality using Francia-Shapiro tests and, when
necessary, variables were transformed and successfully normalized
(x2, x3, log x, 1/x2, √x, 1/√x; see Table 3). Baseline data were
expressed as median and interquartile range (25-75), or means and SD
when indicated. Means of each continuous variable were compared
by one-way analysis of variance with Bonferoni post-hoc tests. The
shapes of distributions were compared using Kruskal-Wallis tests.
Non-parametric comparisons were made by chi-square tests. Within-
group (A, B or C) differences were assessed using paired t tests, then
mixed linear regressions, which take into account the repeated mea-
sure design, were used to evaluate outcome changes over time (0, 6
and 12 months) according to the effects of intervention while
adjusting for age and gender. After starting the intervention, we
noticed an error in the recruitment of two subjects in group A, in that
they did not meet the inclusion criteria (one girl was only overweight
and one boy had a psychiatric disorder and cognitive retardation
which limited his participation in a lifestyle programme). They have
been included in the ITT analysis and outcomes did not change after
removing them from the analysis. The statistical software programme
Stata release 14 (College Station, Texas) was used and differences
were considered significant when the P-value was <.05.
2.9 | Costs calculation
During the 6-month trial, treatment A comprised three medical
(600 CHF/630 USD), four dietetic (296.40 CHF/311 USD) and two
medical follow-up consultations (330 CHF/347 USD) plus 44 sessions
of physical activity at the hospital or in a sports club (60 minutes +
30 minutes of preparation per session for six participants per teacher,
660 CHF/693 USD). One hour per child was added for medical coor-
dination (196.10 CHF/206 USD). The direct costs for treatment A
were 1786.10 CHF (1876 USD) for 6 months and 2082.50 CHF (2187
USD) for 12 months. In treatment B, the fixed rate for behavioural
and physical activity sessions, was 4200 CHF (4411 USD). In addition,
patients had three paediatric consultations at 0, 3 and 6 months
(444.60 CHF/467 USD) and two follow-up consultations (296.40
CHF/311 USD). The direct costs for treatment B were 4644.60 CHF
(4877 USD) for 6 months and 4941 CHF (5189 USD) for 12 months.
The control group received standard care including one paediatric
consultation every 3 months, so the costs were 444.60 CHF
(467 USD) at 6 months and 741 CHF (778 USD) at 12 months.
2.10 | Role of funding sources
The funders were not involved in the study design, data collection,
analysis, interpretation or in the manuscript preparation and decision
to publish.
3 | RESULTS
3.1 | Comparison of groups at baseline
There were no statistically significant differences between groups for
baseline physical characteristics, blood metabolism and arterial func-
tion (Table 1). The vascular age was advanced in 74% of children.
Eighty seven percent of subjects were Caucasian and the
remaining 4% were African, 4% Asian and 5% Hispanic; 57%, 42% and
55% of subjects had a Swiss citizenship and 24%, 42% and 41% were
from the European region (Portugal, Spain, Italy, France, Serbia and
Kosovo) in group A, B and C, respectively.
Sixty two percent of mothers were overweight (58%, 71% and
52% in A, B and C, respectively) and 28% of them had obesity (37%,
29% and 19% in A, B and C, respectively); 19% of children had both
parents with obesity, and 23% had a family history of type 2 diabetes.
3.2 | Effects of treatment A and B
Sixty-six (89%) out of 74 children received the 6-month intervention
as assigned. The retention rate was 90%, 90% and 86% of subjects in
group A, B and C, respectively, and the compliance, which was deter-
mined as the proportion of attended behavioural and physical activity
sessions during the 6-month intervention, was 87% and 50% in
group A, and 64% and 45% in group B, respectively (excluding chil-
dren that attended sports club). The adherence, which was the
FARPOUR-LAMBERT ET AL. 5 of 12
TABLE 1 Baseline physical characteristics, metabolism and arterial function in pre-pubertal children with obesity (n = 74)
Variables
Group A: Individual delivery Group B: Group delivery Group C: Control
P-value*N Mean/Median SD/IQR N Mean/Median SD/IQR N Mean/Median SD/IQR
Gender (M, %) 21 13 (62) 31 12 (39) 22 13 (59) .18
Age (years)# 21 9.5 1.2 31 9.7 1.1 22 9.7 1.0 .77
Physical characteristics
Height (cm) 21 138.0 9.0 31 140.0 9.0 22 140.0 13.0 .82
Body weight (kg) 21 46.1 16.0 31 50.2 10.3 22 47.9 17.1 .66
BMI (kg × cm2) 21 23.7 4.7 31 25.8 2.9 22 24.8 6.0 .67
BMI z-score CDC 21 2.1 0.5 31 2.1 0.3 22 2.0 0.5 .88
BMI z-score WHO 21 2.8 0.7 31 2.8 0.6 22 2.7 0.8 .91
Waist circumference (cm) 21 79.0 13.0 31 80.0 12.5 22 80.0 12.0 .89
Waist-to-height ratio 21 0.6 0.1 31 0.6 1.0 22 0.6 0.1 .88
Total body fat (%) 20 41.4 9.2 31 44.1 4.1 21 44.0 5.2 .34
Abdominal fat (%) 20 49.7 8.7 31 52.5 5.6 21 52.3 7.2 .4
FFM (kg) 20 26.7 5.3 31 27.4 5.1 21 26.5 7.4 .97
VO2 peak (L × min
−1) # 21 1.8 0.4 29 1.7 0.6 19 1.7 0.9 .97
VO2 peak/FFM (mL × kg
−1 × min−1) 20 68.1 11.1 29 64.1 14.1 18 67.5 19.4 .97
Physical activity (cpm) 16 422.4 189.4 22 363.6 229.2 15 399.8 173.3 .26
Blood metabolism
Fasting glucose (mmol × L−1) 21 4.7 0.4 31 4.7 0.6 21 4.6 0.5 .62
Fasting insulin (mU × L−1, % high) 19 12.7 (37) 8.0 31 9.3 (22) 6.8 21 9.5 (5) 4.3 .38
HOMA-IR 19 2.8 1.7 31 1.8 1.3 21 2.1 0.8 .36
TC (mmol × L−1, % high)# 21 4.5 (24) 0.9 31 4.3 (19) 1.1 21 4.4 (19) 0.8 .97
LDL-C (mmol × L−1, % high) 21 2.9 (29) 1.2 31 2.7 (19) 0.7 21 2.9 (14) 1.0 .96
HDL-C (mmol × L−1, % low) 21 1.2 (29) 0.3 31 1.2 (32) 0.5 21 1.2 (19) 0.4 .92
TG (mmol × L−1, % high) 21 0.7 (29) 0.7 31 0.8 (16) 0.7 21 0.7 (5) 0.3 .67
hs-CRP (mmol × L−1) 18 3.6 3.0 26 2.9 2.7 18 2.3 2.8 .09
Arterial function
Office systolic BP (mm Hg) 20 111.4 7.4 28 110.0 12.0 21 111.3 8.7 .88
Office diastolic BP (mm Hg)# 20 69.4 11.2 28 67.7 7.7 21 68.0 9.4 .82
Office systolic BP z-score# 20 0.8 0.7 28 0.7 0.7 21 0.8 1.0 .83
Office diastolic BP z-score# 20 0.7 1.0 28 0.6 0.6 21 0.6 0.8 .78
Office HTN (n systolic/diastolic, %) 20 2/4 20% 28 2/1 7.1% 21 3/3 14.3 .69
24-h systolic BP (mm Hg) 16 113.5 7.0 28 114 12.0 11 116.0 19.0 .82
24-h diastolic BP (mm Hg) 16 67.5 9.0 28 66.0 7.0 11 65.0 12.0 .24
24-h systolic BP z-score# 16 0.8 1.1 28 0.6 1.2 11 0.7 1.2 .89
24-h diastolic BP z-score# 16 0.8 1.5 28 0.1 1.1 11 0.2 1.4 .23
24-h HTN (n syst/diast, %) 16 13/11 81% 28 21/14 75% 11 8/5 73% .85
CIMT (mm) 20 0.53 0.05 30 0.53 0.06 18 0.52 0.13 .87
Einc (mm Hg × 102) 20 892.1 474.1 30 900.6 768.4 18 895.1 780.5 .84
FMD (%) 20 4.2 3.4 30 4.0 3.6 18 7.7 4.3 .35
NTGMD (%) 20 22.9 9.7 30 23.2 11.1 18 22.8 16.4 .81
Notes: Results are shown as median and interquartile range (IQR 25–75), or mean and SD when indicated #. The percentage of abnormal glucose, insulin
and lipids levels is presented in brackets.
Abbreviations: BMI, body mass index; BP, blood pressure; CDC, Centers for Disease Control and Prevention; CIMT, intima-media thickness of the left
common carotid artery; Einc, incremental elastic modulus; FFM, fat-free mass; FMD, flow-mediated dilation; HDL-C, high-density protein cholesterol;
HOMA-IR, homeostasis assessment model of insulin resistance; hs-CRP, high-sensitive C-reactive protein; HTN, hypertension; LDL-C, low-density protein
cholesterol; NTGMD, nitroglycerin-mediated dilation; TC, total cholesterol; TG, triglycerides; VO2 peak, maximal cardiorespiratory fitness; WHO, World
Health Organization.
*The P-values indicate differences between groups (one-way analysis of variance). There is no significant difference.
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proportion of subjects who completed 75% of behavioural sessions,
was 95% in group A and 45% in group B.17
In group A, 10 (48%) of 21 children participated on a weekly basis
in sports club: swimming (n = 3), soccer (n = 2), horse riding (n = 1),
badminton (n = 1), basketball (n = 1), biking (n = 1) and judo (n = 1). In
group B, 16 (52%) of 31 children were involved in sports club: swim-
ming (n = 6), soccer (n = 3), dance (n = 1), gymnastics (n = 2), boxing
(n = 1), basketball (n = 1) and judo (n = 2). The compliance could unfor-
tunately not be evaluated for the sports club participation.
The main reasons for incomplete testing was the time needed
(absence from school) and discomfort of ambulatory BP and arterial
function measures. Only one adverse event was reported during the
intervention: a mild ankle sprain during the physical activity pro-
gramme in Group B.
Body weight and composition parameters treatment effects at
6 and 12 months are presented in Table 2. Mixed effects regression
models with repeated measures predicting changes in physical, meta-
bolic and arterial function parameters, with intervention × time inter-
action, while adjusting for age and gender are shown in Table 3. As
only few ambulatory BP data (n = 6) were available at 12 months,
analysis were only performed from baseline to 6 months.
3.2.1 | Treatment A vs controls
Significant treatment effects at 6 months for abdominal fat (Tables 2
and 3) and hs-CRP (not shown in Table 2, mean difference
− 2.6 mmoll−1, 95% confidence interval [CI] −5.5 to 0.2, P = .002)
were found, whereas physical activity level was not improved (mean
difference −300.7 cpm, 95% CI −568.0 to −33.5, P = .02) in treatment
A (individual treatment) vs controls. At 12 months, there was no sig-
nificant change for any parameter.
At 6 months, we also observed significant within-group reductions
(paired t tests, not shown in tables) in BMICDC z-score (mean differ-
ence −0.06, 95% CI −0.11 to 0.00, P = .02), fasting glucose
(−0.1 mmol × L−1, −0.3 to 0.0, P = .049), insulin (−1.7 mU × L−1, −3.5
to 0.2, P = .04), HOMA-IR (−0.4, −0.7 to 0.0, P = .02), 24 hours dia-
stolic BP z-score (−0.3, −0.2 to 1.2, P = .04), and increases in body
weight (3.8 kg, 2.7 to 4.8, P < .0001), BMI (0.6 kg × m−2, 0.1 to 1.0,
P = .001), waist circumference (1.8 cm, 0.6 to 3.1, P = .004), FFM
(1.9 kg, 1.5 to 2.2, P < .0001), VO2 peak (180.8 L × min
−1, 12.3 to
349.3, P = .02) and FMD (1.3%, −0.3 to 2.9, P = .05).
3.2.2 | Treatment B vs controls
Significant treatment effects were found at 6 months for BMI,
BMICDC z-score, abdominal fat (Table 3) and hs-CRP level (not shown;
mean difference −1.3 mmol × L−1, 95% CI −4.0 to 1.5, P = .004), in
treatment B (group treatment) vs controls. At 12 months, further
improvement in BMI, BMICDC z-score, total and abdominal fat, as well
as NTGMD (15.0%, −0.76 to 30.7, P = .01) were found.
At 6 months, we also observed significant within-group reductions
(paired t tests, not shown in tables) in BMICDC z-score (mean differ-
ence −0.08, 95% CI −0.13 to −0.02, P = .006), BMIWHO z-score
(−0.15, −0.24 to −0.05, P = .001) and LDL-cholesterol level
(−0.2 mmol × L−1, −0.4 to 0.0, P = .02), whereas body weight (3.1 kg,
2.1 to 4.1, P < .0001), FFM (1.4 kg, 1.0 to 1.8, P < .0001), VO2 peak
(205.8 L × min−1, 81.7 to 329.8, P = .002) and Einc (546.5 mm
Hg × 102, 25.0 to 1068.0, P = .02) increased.
TABLE 2 Body weight and composition parameters treatment effects at 6 and 12 months in experimental groups A and B compared with
control group
Non-normalized variables
Treatment effect at 6 months Treatment effect at 12 months
Group A: Individual delivery Group B: Group delivery Group A: Individual delivery Group B: Group delivery
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Body weight (kg) 0.13 −1.28 to 1.55 −0.57 −1.86 to 0.73 1.47 −1.18 to 4.13 −0.90b −3.31 to 1.51
BMI (kg × cm2) −0.21 −0.89 to 0.46 −0.55a −1.16 to 0.06 0.31 −0.89 to 1.50 −0.77a,b −1.86 to 0.32
BMI z-score CDC −0.06 −013 to 0.03 −0.08a −0.15 to 0.00 −0.02 −0.15 to 0.11 −0.10a,b −0.22 to 0.01
BMI z-score WHO −0.03 −0.17 to 0.11 −0.10 −0.23 to 0.03 0.06 −0.16 to 0.29 −0.09b −0.29 to 0.11
WC (cm) 0.63 −2.86 to 4.12 −0.84 −4.02 to 2.34 −1.09 −2.99 to 5.17 −1.77a,b −5.59 to 2.05
Waist-to-height ratio 0.001 −0.02 to 0.03 −0.008 −0.03 to 0.01 0.03 −0.03 to 0.03 −0.02a −0.04 to 0.01
Total body fat (%) −1.18 −2.62 to 0.27 −1.20 −2.48 to 0.07 −0.33 2.58 to 1.92 −1.65a −3.75 to −0.46
Abdominal fat (%) −2.90a −5.35 to −0.45 −2.23a −4.39 to −0.06 −1.18 −4.19 to 1.82 −3.11a −5.91 to −0.30
Fat-free mass (kg) 0.23 0.51 to 0.97 −0.21 −0.85 to 0.45 0.86 −0.32 to 2.04 0.46 −0.65 to 1.56
Notes: Results are shown as means and 95% CI.
Abbreviations: BMI, body mass index; CDC, Centers for Disease Control and Prevention; CI, confidence interval; WHO, World Health Organization; WC,
waist circumference.
aSignificant treatment effects in experimental groups A (individual delivery) or B (group delivery) compared with control group C using mixed effects
regression model with intervention × time interaction while adjusting for age and gender (intention-to-treat analysis), P < .05.
bSignificant treatment effects in experimental groups A (individual delivery) compared with group B (group delivery) using mixed effects regression model
with intervention × time interaction while adjusting for age and gender (intention-to-treat analysis), P < .05.
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3.2.3 | Comparison between treatment A and B
(non-randomized)
At 6 months, no significant difference was shown between groups A
and B (Tables 2 and 3). At 12 months, changes were significantly
greater for body weight, BMI, BMICDC and BMIWHO z-scores, waist
circumference, physical activity (result not shown; mean difference
131.1 cpm, 95% CI −232.6 to 494.7, P = .03) and Einc (−335.3 mm
Hg × 102, −1144.4 to 473.9, P = .02) in treatment B vs A.
3.3 | Costs calculation
The direct costs were 1786 CHF (1876 USD) at 6 months and 2083
CHF (2188 USD) at 12 months for treatment A, and 4645 CHF (4878
USD) at 6 months and 4941 CHF (5189 USD) at 12 months for treat-
ment B. The later was 2.4-fold more costly than treatment A, and 6.7
more costly than standard care (controls).
4 | DISCUSSION
The evidence to determine the most effective and sustainable type or
setting of intervention is lacking for pre-pubertal children. Our study
showed that both medium-intensity individually delivered interven-
tion (treatment A) and high-intensity group intervention (treatment B)
resulted in significant reductions at 6 months in abdominal fat and
low-grade inflammation (hs-CRP) in pre-pubertal children with obe-
sity, compared to standard care. Treatment B was also effective for
reducing BMI and BMI z-score at 6 and 12 months, when compared
to controls, as well as waist circumference, total and abdominal fat
and vascular reactivity mediated by smooth muscle cells (NTGMD) at
12 months. Carotid arterial stiffness was also reduced at 12 months in
treatment B compared to A.
4.1 | Effects on BMI
A decrease in BMI z-score during growth is of particular importance
because it is inversely associated with the risk of coronary heart dis-
ease in adulthood.18 In a recent systematic review including 70 studies
in 6 to 11 years old children, a mean BMI z-score change of −0.06
(95% CI −0.10 to −0.02) was reported after intervention, the majority
of studies using CDC references (only one using WHO references).9
However, only half of studies included a post-intervention follow-up
(range 1-30 months). The effect observed in treatment B was of simi-
lar magnitude (BMICDC z-score −0.08) compared to controls, and fur-
ther changes were observed at 12 months (−0.10).
Treatment A did not lead to significant reduction of BMI z-score
at 6 or 12 months, likewise a previous study evaluating the effects of
a similar individually delivered intervention in 6 to 14-year-old chil-
dren and adolescents.19 Only a few studies have examined the effec-
tiveness and generalizability of such intervention in teenagers.20,21
4.2 | Effects on body composition and
cardiometabolic health
BMI is not a direct measure of body composition, thus changes in fat
mass may be confounded with changes in FFM.22 The significant
decreases in abdominal fat and hs-CRP observed in treatment A and B
have important implications for the cardiometabolic health of this at
risk population.23 Within-group changes at 6 months in treatment A
were also significant for glucose, insulin and HOMA-IR, but no treat-
ment effect could be demonstrated when compared to controls, prob-
ably due to small sample size, the statistical power being calculated
based on the primary outcome BMI z-score change.
Visceral obesity and associated insulin resistance increase CVD
risk by classical factors (dyslipidaemia, glucose dysregulation, hyper-
tension and vascular dysfunction), as well as risk factors secreted by
adipocytes and macrophages infiltrating adipose tissue (adipokines,
pro-inflammatory cytokines and hypofibrinolytic factors) that,
together, might lead to increased oxidative stress, arterial dysfunction
and promoting atherosclerosis.24 Persistent low-grade inflammation
plays a major role in the development of atherosclerosis and several
large-scale prospective studies have demonstrated continuous rela-
tions between hs-CRP, the risk of CVD and vascular mortality.25 In
children with obesity, a pro-inflammatory state has also been demon-
strated even without established comorbidities,26 and hs-CRP was
associated with pre-clinical signs of atherosclerosis.27 In addition, a
recent study has shown that pre-pubertal insulin-glucose metabolism
is associated with adult CVD risk and markers of atherosclerosis.28
Reduced hs-CRP inflammation markers have also been reported in
previous lifestyle interventions in children with obesity.29,30
4.3 | Effects on arterial parameters
In children and adolescents, BMI is strongly related to high BP.31 At
baseline, moderate hypertension ranged from 20% at rest to 81% by
ambulatory monitoring, but no effect of treatment A or B could be
seen compared to controls. The attendance rate at exercise sessions
was low in both groups and physical activity levels decreased in group
A compared to B. We previously reported significant improvement of
BP after a 3-month moderate-to-vigorous exercise training pro-
gramme including three sessions per week. A dose-effect relationship
may explain differences between studies.11
Endothelial cell dysfunction is considered the first stage of athero-
sclerosis, and low FMD has been reported previously in children with
obesity,32 in association with increased arterial stiffness and systemic
hypertension,10 whereas signs of arterial wall remodelling are detect-
able later during adolescence.33 In our study, a within-group A
increase of FMD (+1.3%) was observed, suggesting improved endo-
thelial cell function. As a meta-analysis of 5547 adults associated a
1% increase in FMD with a 13% decrease in cardiovascular events,34
an improvement in FMD of 1.3% in this at-risk paediatric population
would be expected to ameliorate their cardiovascular risk profile.
However, the treatment effect was not significant compared to con-
trols, probably due to the procurement of standard care in controls, a
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small sample size and missing longitudinal data. In children aged 9 to
12 years (pre-pubertal and pubertal), a significant increase in FMD
(+1.2% at 6 weeks, +1.7% at 12 months) was previously reported after
a high-intensity exercise training programme was combined with a
group lifestyle intervention comprising of a balanced hypocaloric
diet.35 Diet and exercise together, and maintenance of exercise at
12 months, were associated with a significantly greater improvements
in endothelial function.
We also observed improvement of vascular reactivity mediated by
smooth muscle cells (NTGMD) at 12 months in treatment B vs con-
trols. In adults with metabolic syndrome, a reduction of the inflamma-
tory state improves both endothelium-dependent and endothelium-
independent vasodilator reactivity.36
Arterial stiffness is a consequence of arteriosclerosis, the process
of arterial wall thickening and loss of elasticity that occurs with the
onset of vascular disease. In this study, vascular age was advanced in
a large proportion of children and a reduction of Einc was found at
12 months in group B, compared to group A (non-randomized). We
showed previously that moderate-to-vigorous exercise at least twice
a week during 6 months resulted in reduced arterial stiffness and sta-
bilization of CIMT.11 Adult studies have shown that arterial stiffness
may predict CVD and mortality.37 We may therefore hypothesize that
high-intensity group intervention may have a long-term clinical impact
on cardiovascular health; however, results remain to be verified
in a RCT.
4.4 | Costs
The costs of treatment B were twice as much as treatment A. Few
studies have investigated the cost estimates of childhood obesity
management and showed a wide range of costs and evidence.5,38,39
We found only one with a full economic evaluation.36 Authors con-
cluded that simple multi-component obesity interventions (hospital-
based or nurse-led in primary care) can be provided at relatively low
cost per 0.1 BMI improvement compared to an intensive and costly
behaviour modification tool aimed at encouraging slower eating and
better recognition of satiety.
4.5 | Strength and limitations
The strengths of this RCT were the evaluation of both benefits and
harms, and the assessment of long-term efficacy. The possibility to
choose between two treatment options facilitated the implementation
of this research into clinical practice. A high retention rate in treat-
ment arms A and B was also a strength compared to most obesity
management centres reports.8 The calculation of direct costs of treat-
ment may be of special interest for policy makers and health insurance
providers. Ideally, children should have been randomized in three
groups to avoid selection bias, however it was difficult to impose a
high-intensity group intervention to parents who could not attend
sessions on a fixed day, time and location. The high compliance rate in
the individually delivered intervention (treatment A) may be due to a
smaller amount of visits and hours required. The choice and quality of
the measures performed allowed us to evaluate the effects of the trial
not only on BMI z-score, but also on markers of cardiometabolic
health. However, the sample size calculation was based on the pri-
mary outcome: BMI z-score and not on these secondary outcome
markers, which may have influenced the results.
The main limitation of this study was the time needed for testing
(5 hours), which led to absences from school, and the discomfort of
arterial parameters measures resulting in incomplete follow-up data.
The higher drop-out rate in the control group compared to interven-
tion groups was also a limitation for the interpretation of follow-up
analysis. In patients with obesity, hypertension may be due to altered
autonomous system activity and sleep apnoea, although these were
not measured in our study. The control group received standard care,
even if considered minimal, and this may have attenuated the treat-
ment effects between groups. The attendance rate of children partici-
pating in sports club could not be evaluated, and this may also explain
differences between groups. Finally, it would have been useful to
know whether children changed their diet during intervention; data
were collected using 3-day food records but were too poor to be
analysed.
5 | CONCLUSIONS
The increasing prevalence of childhood obesity globally is likely to
lead to a tsunami of NCDs in the coming decades unless urgent action
is taken. It must be considered as a chronic disease to increase socie-
tal awareness, improve care and prevent the significant comorbid clin-
ical and psychosocial problems.40 However few children with obesity
receive adequate treatment, and cost-effective interventions are
urgently needed before puberty.
Both 6-month lifestyle interventions resulted in significant reduc-
tions in abdominal fat and low-grade inflammation (hs-CRP) in pre-
pubertal children with obesity, compared to standard care. To our
knowledge, this is the first study showing such changes after an indi-
vidually delivered intervention in this population. We also showed
that the high-intensity group intervention was effective in reducing
BMI and BMI z-score, as well as vascular reactivity mediated by
smooth muscle cells and carotid arterial stiffness. These findings are
important given the global increases in childhood obesity and in the
promotion of cardio-metabolic health and prevention of NCDs later in
life. Individually delivered intervention is less costly than group inter-
vention, facilitating its dissemination at large scale as it could be easily
transferred to a primary care setting, in collaboration with sports clubs
and physical education teachers.
However, to improve the management of obesity in children, both
in individual and group setting, healthcare systems need to be
adapted; the nutritional, psychological and physical therapy should be
covered by health insurance, and healthcare workers should be
trained to treat obesity similarly to other chronic diseases of child-
hood.40 Primary care providers could then play a major role in the
early treatment of childhood obesity and prevent the burden of CVD
later in life. Further research is now needed to determine the optimum
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intensity and composition of interventions in this age group, and long-
term efficacy at 5 or 10 years. Treatment effects using different BMI
z-score references should also be evaluated.
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